Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends
This article was originally published in Drug Channels.
In a competitive market, pharma companies are increasingly relying on various datasets to drive their decision-making. With so many disparate sources, however, data standardization presents a challenge, especially for companies eager to use predictive analytics tools. In a recent survey of 125 pharma executives, nearly half cited data integration and cleanliness as the primary roadblocks to adopting technologies like AI.
Harmonized data is a prerequisite for generating actionable insights, with or without sophisticated data science…
As payers grapple with their ever-increasing spend on healthcare services, many are entering into various arrangements with pharma manufacturers to help mitigate their risk when paying for cell, gene and specialty therapies—which often have price tags ranging from several hundred thousand to millions of dollars. A warranty-based agreement is one approach that can benefit both stakeholders. These agreements can potentially boost the uptake of high-cost treatments by increasing the likelihood that payers will cover products, particularly those with unclear efficacy or…
To fully understand how payers impact patient access, pharma companies should be evaluating payers using multiple datasets, including both coverage/restriction data and claims data. While payer policies indicate how payers plan to manage a product or service, medical and pharmacy claims reveal how payers actually manage that product in reality.
Taken together, claims and coverage data generates a wealth of information about how patients move through the healthcare system—and how payer behavior impacts their access to treatment. What’s driving rejections of…
For the past decade, biosimilar adoption in the U.S. has proceeded at a relatively slow pace, due in large part to limited financial rebates for payers and provider preferences for biologics. Recent research suggests that utilization is finally picking up steam as more health plans place both biosimilars and their reference biologics on preferred formulary tiers.
A Health Affairs study found that preferred coverage of a single biologic declined by 47% between 2017 and 2022, while preferred coverage of multiple drugs…
When the FDA approved the first cell and gene therapy (CGT) for hemophilia almost two years ago, it represented a massive leap forward in treating the bleeding disorder. The one-and-done agents offer the promise of a cure, giving patients the prospect of freedom from the disease without regular treatments.
Although three hemophilia CGTs are now on the U.S. market, access has not yet met expectations, and only a handful of patients have received treatment to date. These therapies have been slow…
Lab data has become an increasingly essential dataset for pharmaceutical companies at all stages of the product life cycle. A key use case for our MMIT clients is using lab data for commercial targeting. Since lab tests often represent one of the earliest data points in a patient’s diagnostic journey, pharma companies are using lab results to identify potential patients and their physicians in time to directly impact the patient’s treatment plan. By coupling lab data with clinical expertise, pharma companies…
In the complex healthcare analytics landscape, understanding the nuances of open and closed claims is critical for researchers and analysts. Open and closed claims each offer unique insights into the patient journey.
Open claims, sourced from various clearinghouses and warehouses across the U.S., present a vast collection of data, while closed claims, adjudicated by insurers, provide a detailed, individualized perspective. Open claims are rather like a wide-angle view of the forest, whereas closed claims are more like a view of the…
Our first post in this series discussed how early market access research, conducted in the 12-18 months before launch, helps pharma companies identify differentiators and establish accurate expectations.
As your organization moves closer to launch, your market access team will need to establish a commercially focused definition for your patient population. You’ll need to identify treating physicians, define the current standard of care, and establish how your brand will fit into the existing landscape. Critically, your team will also need to…
Before physicians prescribe a new therapy, they need to trust that it is the most effective and appropriate treatment for an individual patient. They need education on the drug’s efficacy and safety, dosing and administration, and the clinical criteria that define eligibility. They also need to know if the drug is affordable and accessible for their patients.
Although pharma sales reps typically convey all this information to HCPs during their in-person meetings, physicians have become much more selective about the companies…
According to our 2024 State of Patient Access survey, 81% of pharma companies are launching their market access planning much earlier than they did five years ago. By Phase I, one-third of pharma companies are already engaged in market access research, with most pharma companies (54%) engaged by Phase II – III.
What can manufacturers hope to learn about the competitive landscape so far in advance? From identifying a brand’s most valuable differentiators to establishing accurate expectations for launch, early market access…
